Who Paid My Doc
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
ClinicalTrials.gov NCT05127954
Research payments
$10,314,859
Through program year 2025, $10,314,859 in research payments was reported against Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17), across 2,632 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT05127954
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,903,955 | 701 |
| 2024 | Research | $4,491,116 | 1,016 |
| 2023 | Research | $2,871,777 | 684 |
| 2022 | Research | $1,048,010 | 231 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kristi Trimm Ridgeland, MS Named on 108 payments
- James Renfroe Gulf Breeze, FL Named on 75 payments
- Jackson Rhudy Salt Lake City, UT Named on 75 payments
- James Fry Nashville, TN Named on 65 payments
- Carlos Escasena Coral Gables, FL Named on 48 payments
- Niaz Ausaf Sarasota, FL Named on 47 payments
- Samir Arora Powell, OH Named on 45 payments
- Jessica Schroeder Washington, DC Named on 39 payments
- Khozema Palanpurwala Houston, TX Named on 38 payments
- Vanna Gold Lampasas, TX Named on 34 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.